[{"orgOrder":0,"company":"Protalix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PRX-105","moa":"Acetylcholinesterase (AChE)","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Protalix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protalix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Protalix \/ Undisclosed"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Noveome Biotherapeutics \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ IQVIA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isoamyl Nitrite","moa":"ANP-1 receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Haiyan Li","sponsor":"Food and Drug Administration | Spaulding Clinical, LLC | Bioclinica | Peking University","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Haiyan Li","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haiyan Li \/ Food and Drug Administration | Spaulding Clinical, LLC | Bioclinica | Peking University","highestDevelopmentStatusID":"6","companyTruncated":"Haiyan Li \/ Food and Drug Administration | Spaulding Clinical, LLC | Bioclinica | Peking University"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"University of Cambridge | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ University of Cambridge | AstraZeneca"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Pennsylvania \/ Amarin","highestDevelopmentStatusID":"6","companyTruncated":"University of Pennsylvania \/ Amarin"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"National Cancer Institute | Nerium Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ National Cancer Institute | Nerium Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"MD Anderson Cancer Center \/ National Cancer Institute | Nerium Biotechnology"},{"orgOrder":0,"company":"101 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"101-PGC-005","moa":"Glucocorticoid receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"101 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"101 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"101 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Glycerol Phenylbutyrate","moa":"Glutamine","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoAgents \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CytoAgents \/ Undisclosed"},{"orgOrder":0,"company":"Partner Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Partner Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Partner Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Partner Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The First Affiliated Hospital with Nanjing Medical University","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"The First Affiliated Hospital with Nanjing Medical University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital with Nanjing Medical University \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital with Nanjing Medical University \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"POLB 001","moa":"MAPK\/p38","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Poolbeg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biomedical Advanced Research and Development Authority","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Biomedical Advanced Research and Development Authority","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomedical Advanced Research and Development Authority \/ Rho Inc","highestDevelopmentStatusID":"6","companyTruncated":"Biomedical Advanced Research and Development Authority \/ Rho Inc"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"University Health Network, Toronto | Canadian Blood Services","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Canadian Blood Services","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ University Health Network, Toronto | Canadian Blood Services"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"PRA Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"89-Zr GSK3128349","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ PRA Health Sciences","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ PRA Health Sciences"},{"orgOrder":0,"company":"SRI International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Undisclosed"},{"orgOrder":0,"company":"SRI International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"SRI International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRI International \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SRI International \/ Undisclosed"},{"orgOrder":0,"company":"HOPO Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"HOPO 14-1","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"HOPO Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"HOPO Therapeutics \/ BARDA","highestDevelopmentStatusID":"6","companyTruncated":"HOPO Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Kwang Dong Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"KD101","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Kwang Dong Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kwang Dong Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MR902","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ricin Toxin","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ricin Toxin Vaccine","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SHR-1603","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luye Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
POLB 001 is a novel small molecule, orally administered p38 MAP kinase inhibitor. It is being evaluated under in-vivo studies for the treatment of cytokine release syndrome.
Details :
HOPO 14-1 (3,4,3-Li(1,2-hopo) is a novel orally administered experimental drug, designed to act as a defence against radioactive threats and is being investigated to treat radioactive contamination in the body.
Details :
Mycapssa® (oral octreotide) is approved by the FDA and the EC for long-term maintenance treatment in acromegaly patients who have responded to and tolerated injectable treatment with octreotide or lanreotide (i.e. somatostatin analogs (SSAs)).
Details :
HOPO 14-1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Toxicity, Chemical.
Details :
101-PGC-005 is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glucocorticoids Toxicity.
Details :
Sargramostim is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Physiological Effects of Drugs.
Details :
Study evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SIAN (stabilized isoamyl nitrite), a treatment being developed for known or suspected acute cyanide poisoning.
Reset All
